The Safety and Efficacy of Remimazolam Compared to Dexmedetomidine for Awake Tracheal Intubation by Flexible Bronchoscopy: A Randomized, Double-Blind, Controlled Trial
Qiumiao Chen,Bin Qin,Manqing Zhang,Yumei Zhou,Xiaotong Shi,Yubo Xie
DOI: https://doi.org/10.2147/dddt.s446222
IF: 4.3188
2024-03-29
Drug Design Development and Therapy
Abstract:Qiumiao Chen, 1 Bin Qin, 2 Manqing Zhang, 2 Yumei Zhou, 2 Xiaotong Shi, 2 Yubo Xie 1, 3 1 Department of Anesthesiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, People's Republic of China; 2 Department of Anesthesiology, College of Stomatology, Hospital of Stomatology, Guangxi Medical University, Nanning, People's Republic of China; 3 Guangxi Key Laboratory of Enhanced Recovery After Surgery for Gastrointestinal Cancer, The First Affiliated Hospital of Guangxi Medical University, Nanning, People's Republic of China Correspondence: Yubo Xie; Xiaotong Shi, Email ; Background: Remimazolam is a novel ultra-short-acting benzodiazepine sedative that has the potential to be an alternative for procedural sedation due to its rapid sedation and recovery, no accumulation effect, stable hemodynamics, minimal respiratory depression, anterograde amnesia effect, and specific antagonist. Here, we aimed to compare the safety and efficacy of remimazolam with dexmedetomidine for awake tracheal intubation by flexible bronchoscopy (ATI-FB). Methods: Ninety patients scheduled for ATI-FB were randomly divided into three groups, each consisting of 30 cases: dexmedetomidine 0.6 μg/kg + sufentanil (group DS), remimazolam 0.073 mg/kg + sufentanil (group R 1 S), or remimazolam 0.093 mg/kg + sufentanil (group R 2 S). The primary outcome was the success rate of sedation. Secondary outcomes were MOAA/S scores, hemodynamic and respiratory parameters, intubation conditions, intubation time, tracheal intubation amnesia, and adverse events. Results: The success rates of sedation in groups R 2 S and DS were higher than that in group R 1 S (93.3%, 86.7%, respectively, vs 58.6%; P = 0.002), and intubation conditions were better than those in group R 1 S ( P < 0.05). Group R 2 S had shorter intubation times than groups R 1 S and DS ( P = 0.003), and a higher incidence of tracheal intubation amnesia than group DS ( P = 0.006). No patient in the three groups developed hypoxemia or hypotension, and there were no significant differences in oligopnea, PetCO 2 , or bradycardia ( P > 0.05). Conclusion: In conclusion, both DS and R 2 S had higher success rates of sedation, better intubation conditions, and minor respiratory depression, but R 2 S, with its shorter intubation time, higher incidence of anterograde amnesia, and ability to be antagonized by specific antagonists, may be a good alternative sedation regimen for patients undergoing ATI-FB. Keywords: remimazolam, dexmedetomidine, difficult airways, awake tracheal intubation Awake tracheal intubation (ATI) is a recommended technique for airway management in patients with predictable difficult airways. 1–3 However, when ATI induces a strong stress response in the body, patients may experience malignant cardiovascular events due to a sharp increase in catecholamine concentrations, as well as severe complications such as airway injury or failure of intubation due to coughing, irritability, and trunk twisting. 4 As a result, in addition to perfect airway local anesthesia, appropriate sedatives and analgesics should be administered before intubation to reduce patients' stress reaction and discomfort during tracheal intubation, thereby increasing patients' tolerance of tracheal intubation, reducing complications, and improving the success rates of intubation. 5,6 To ensure safety, patients with difficult airways need to maintain spontaneous breathing and minimize airway collapse during tracheal intubation. Hence, sedatives and analgesics should be quickly metabolized, minimally respiratory depressing, and can be antagonized. Currently, frequently used regimens of sedatives and analgesics for awake tracheal intubation by flexible bronchoscopy (ATI-FB) include midazolam and dexmedetomidine alone or combined with opioids. Dexmedetomidine is the most widely used therapeutically for ATI because it results in arousable sedation and has little respiration and hemodynamic effects. 7 Dexmedetomidine, on the other hand, has a slow metabolism and no specific antagonist. As a result, over-sedation with dexmedetomidine can be fatal in patients with difficult airways. Furthermore, dexmedetomidine has no pharmacologic anterograde amnesia, and patients may remember the unpleasant tracheal intubation procedure, which can have psychological consequences. Therefore, it is of great clinical significance to seek safe, effective, and comfortable sedatives for ATI-FB. Remimazolam is a novel type of ultra-short-acting benzodiazepine that ac -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal